Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of SGM-101 for intraoperative detection of colorectal brain metastases
2020-003804-15Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- May 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sgm-101 in colorectal cancer (CRC), sponsored by Leiden University Medical Center. Primary endpoint: Primary: Concordance between intraoperative fluorescence assessment and reference standard. Started May 2022; status: active.
02
Drugs
sgm-101
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-003804-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003804-15.